CMT4A

GDAP1 | 2002

Illustration of a DNA double helix overlaid on nerve cells, with text reading ‘Experts in CMT: CMT Genes and Subtypes Database

CMT4A s caused by mutations in the GDAP1 gene. This gene provides instructions for producing ganglioside-induced differentiation-associated protein 1, a protein involved in mitochondrial dynamics and cellular stress responses in peripheral nerves. Mutations in the GDAP1 gene disrupt normal mitochondrial function in the peripheral nerves, leading to impaired nerve signal transmission.

CMT4A is autosomal recessive, meaning that both of the gene’s copies must have a CMT-causing mutation to cause this subtype.

Clinical Features

Symptom onset in CMT4A is typically before age 3, beginning in the lower limbs and progressing to the upper body. Progression to severe disability is often rapid. Nerve conduction studies usually show slowed conduction velocities and somewhat reduced amplitudes, consistent with a demyelinating form of CMT. When a nerve conduction study shows an axonal form of CMT, autosomal recessive CMT2K is the diagnosis.

CMT4A symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • A steppage-style walking pattern
  • Reduced sensation
  • Reduced or absent reflexes
  • Foot deformities, including high arches and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Kyphoscoliosis (kyphosis + scoliosis)
  • Balance difficulties
  • Additional symptoms not listed here

Disease Course

CMT4A is typically a severe disease with an early onset, rapidly progressing to significant disability. Life expectancy, however, is not reduced.

Clinical Basics

Subtype
CMT4A

Classification
CMT4

Neuropathy Type
Demyelinating

Inheritance Pattern
Autosomal Recessive

Genetic Context

HGNC-Approved Gene Symbol
GDAP1

Gene Full Name
Ganglioside-Induced Differentiation-Associated Protein 1

Chromosome
8q21.11

Zygosity of Responsible Variant
Homozygous or Compound Heterozygous

Mitochondrial Involvement
Yes

ClinVar Pathogenic Variants

View CMT4A ClinVar Variants

More Info

Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Ganglioside-Induced Differentiation-Associated Protein-1 is Mutant in Charcot-Marie-Tooth Disease Type 4A/8q21

Authors

Baxter, R. V., Ben Othmane, K., Rochelle, J. M., Stajich, J. E., Hulette, C., Dew-Knight, S., Hentati, F., Ben Hamida, M., Bel, S., Stenger, J. E., Gilbert, J. R., Pericak-Vance, M. A., & Vance, J. M.

Publication Date
January 3, 2002

Updated: February 7, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.